<DOC>
	<DOCNO>NCT00680667</DOCNO>
	<brief_summary>RATIONALE : Coriolus versicolor mushroom extract may slow growth cancer cell may effective treatment breast cancer . PURPOSE : This phase I trial study side effect best dose coriolus versicolor extract treat woman stage I , stage II , stage III breast cancer finish radiation therapy .</brief_summary>
	<brief_title>Clinical Trial Trametes Versicolor Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose oral coriolus versicolor extract woman stage I-III , estrogen receptor- and/or progesterone receptor-negative positive ( 1/26/2009 ) , infiltrate ductal adenocarcinoma breast recently complete standard post-surgery radiotherapy . Secondary - To determine feasibility measure change fatigue quality life patient treated drug . - To characterize toxicity drug patient . - To gather preliminary data compare baseline post-treatment immunologic measure , include differential blood count ( i.e. , WBC ) , natural killer cell activity , phagocytic index , regulatory cell assay , T/B/NK cell population subset assay , peripheral blood mononuclear cell production level interferon gamma , tumor necrosis factor-alpha patient . OUTLINE : Patients receive oral coriolus versicolor extract twice daily 6 week . Patients undergo quality life fatigue assessment baseline , weekly study , 3-week follow-up visit . Blood sample collect periodically immunological marker study . Samples analyze T-regulatory cell , T-and B-lymphocyte , NK cell activity peripheral blood mononuclear cell ( PBMC ) , phagocytic index monocyte granulocyte , cytokine secretion upregulation flow cytometry , cytotoxicity assay , cytolysis assay , T-regulatory cell assay , T/B/NK cell population subset assay . Changes production tumor necrosis factor-alpha interferon-gamma serum supernatant PBMCs analyze via standard enzyme-linked immunosorbent assay . After completion study treatment , patient follow 3 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Diagnosis , within previous 12 month Stage IIII , infiltrate ductal adenocarcinoma breast undergone surgery chemotherapy able begin study treatment within 5 day last dose radiotherapy Estrogen and/or progesterone receptornegative positive Willing eat consistent diet throughout study , avoid dietary source mushroom Willing avoid take product contain Trametes versicolor , immune modulate medicinal mushroom , herbal product believe immune modulating effect , radiotherapy completion subject 's last clinic visit study . Adequate organ function within 14 day study enrollment include follow : Adequate bone marrow reserve : White blood cell ( WBC ) ≥ 2,000/mm³ , Platelet count ≥ 100,000/mm³ , Hemoglobin ≥ 9 g/dL Hepatic : Bilirubin ≤ 20 % time upper limit normal ( ULN ) , Alkaline phosphatase ≤ 20 % time ULN , AST ALT ≤ 20 % time ULN Renal : Creatinine ≤ 20 % time ULN Nutritional status : Albumin ≥ 3.0 g/dL Negative pregnancy test Voluntary write consent performance studyrelated procedure part normal medical care Pregnant Patients reproductive potential must use approve nonhormonal contraceptive method appropriate 4 week last dose Trametes versicolor . Known allergy fungi , include mushroom Serious concurrent medical psychiatric disorder ( e.g. , active infection uncontrolled diabetes ) , opinion investigator , would compromise safety patient patient 's ability complete study Receipt hematopoietic growth factor ( e.g. , Neupogen™ , Epogen™ ) within previous 4 week Unwilling maintain consistency type dose concurrent complementary alternative medicine therapy Unwilling discontinue exclude medication supplement</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ductal breast carcinoma</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
</DOC>